Valneva (NASDAQ:VALN) Sees Large Volume Increase – What’s Next?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) saw an uptick in trading volume on Friday . 12,565 shares traded hands during trading, an increase of 0% from the previous session’s volume of 12,527 shares.The stock last traded at $9.51 and had previously closed at $9.42.

Wall Street Analyst Weigh In

Several research firms have weighed in on VALN. Wall Street Zen cut Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Valneva in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.00.

Valneva Price Performance

The firm has a fifty day moving average of $9.13 and a 200 day moving average of $9.24. The company has a current ratio of 1.78, a quick ratio of 1.36 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $785.32 million, a P/E ratio of -6.33 and a beta of 1.83.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Thursday, November 20th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.31). The company had revenue of $34.01 million for the quarter, compared to analysts’ expectations of $48.85 million. Valneva had a negative net margin of 57.81% and a negative return on equity of 59.44%. On average, equities research analysts anticipate that Valneva SE Sponsored ADR will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. VSM Wealth Advisory LLC increased its stake in shares of Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Valneva in the fourth quarter worth about $44,000. JPMorgan Chase & Co. bought a new position in shares of Valneva in the third quarter worth about $124,000. Marex Group plc purchased a new position in shares of Valneva during the 2nd quarter valued at about $64,000. Finally, Frazier Life Sciences Management L.P. bought a new position in shares of Valneva during the 2nd quarter valued at approximately $8,240,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.